Ravaud, Alain

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 5,807

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 4,656

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 3,019

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 1,408

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,260

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 590

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 585

Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy

Capuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., & Dantzer, R. (2002) · Molecular Psychiatry

Tryptophan and brain disordersTreatment of Major Depression

Cited by 473

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 224

Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy

Capuron, L., Ravaud, A., Gualde, N., Bosmans, E., Dantzer, R., Maes, M., & Neveu, P. J. (2001) · Psychoneuroendocrinology

Tryptophan and brain disordersTreatment of Major Depression

Cited by 201

Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient's Initial Affective State

Capuron, L., & Ravaud, A. (1999) · New England Journal of Medicine

Tryptophan and brain disordersCancer survivorship and care

Cited by 169

Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-α Treatments in Cancer Patients

Capuron, L., Ravaud, A., & Dantzer, R. (2001) · Psychosomatic Medicine

Cancer-related cognitive impairment studiesTryptophan and brain disorders

Cited by 148

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double‐blind, placebo‐controlled, phase 2 study

Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012) · Cancer

Renal cell carcinoma treatmentAngiogenesis and VEGF in Cancer

Cited by 110

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

Lavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., et al. (2018) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 63

Inhibiteurs de mTOR : temsirolimus et évérolimus dans le traitement du cancer du rein

Ravaud, A., Bernhard, J.-C., Gross-Goupil, M., Digue, L., & Ferriere, J.-M. (2010) · Bulletin du Cancer

Renal cell carcinoma treatmentPI3K/AKT/mTOR signaling in cancer

Cited by 14